Dendreon Corp. (NASDAQ:DNDN): After the company’s third quarter Provenge sales missed expectations, William Blair lowered their price target for Dendreon Corp. They expect sales of the drug to remain challenged and keep an Underperform rating on the stock.
Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR): Piper Jaffray said that additional data for Questcor Pharmaceuticals, Inc.’s Acthar for Nephrotic Syndrome was presented at the American Society of Nephrology meeting. The firm believes that growing evidence of Acthar’s benefit in the Nephrotic Syndrome setting points to the continuation of a strong managed care access. After Cerium received orphan designation from the Federal Drug Administration, Piper believes that concern regarding Synacthen is not a risk to Questcor shares and keeps a Neutral rating on the stock. However, they think that shares at current levels represent an attractive near-term buying opportunity.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
Flowserve Corp. (NYSE:FLS): After the company reported stronger than expected results, RBC Capital increased their target on Flowserve Corp. The firm expects the company’s margins to increase and they maintain Outperform rating.
Gardner Denver Inc. (NYSE:GDI): After the company put itself up for sale, RBC Capital increased their target on Gardner Denver Inc. The firm maintains an Outperform rating on the stock.
Qualcomm Incorporated (NASDAQ:QCOM): Morgan Stanley expects Qualcomm Incorporated to report an inline to slightly better fourth quarter. The firm believes their first quarter guidance to be very strong and recommends purchase ahead of the quarter. Shares are Overweight rated with a $73 target.
Don’t Miss: Android vs iOS: The Only Game Left in Town?